Literature DB >> 24471966

Immunohistochemical staining patterns of cytokeratins 13, 14, and 17 in oral epithelial dysplasia including orthokeratotic dysplasia.

Aiko Nobusawa1, Takaaki Sano, Akihide Negishi, Satoshi Yokoo, Tetsunari Oyama.   

Abstract

Diagnosis of the exact grade of oral epithelial dysplasia is difficult, and interobserver variations in grading are common. The aim of this study was to investigate the expression patterns of cytokeratins (CKs) in dysplastic oral epithelia, to identify useful double immunostaining diagnostic markers. Immunoexpression of CK13, CK14, CK17, and Ki-67 were investigated in 21 normal epithelial specimens and 146 epithelial dysplasia specimens. In epithelial dysplasia specimens, orthokeratotic dysplasia (OKD) was identified using CK10 immunostaining. Most mild dysplasia specimens were CK13+ and CK17-. In moderate dysplasia, CK13 expression tended to be lower and CK17 expression tended to be higher than in mild dysplasia. All carcinoma in situ (CIS) specimens were CK17+. In differentiated type CIS specimens, CK13 expression was weakly positive. Most epithelial dysplasia specimens were CK14+. There were no significant differences in the expression patterns of CKs between OKD and non-OKD specimens in any of the grades of dysplasia. These results indicate that CK14 expression can be used to detect early epithelial dysplasia, and that CK13 and CK17 expression are useful for detecting neoplastic changes.
© 2014 The Authors. Pathology International © 2014 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  cytokeratins; double immunostaining; oral epithelial dysplasia; orthokeratotic dysplasia

Mesh:

Substances:

Year:  2014        PMID: 24471966     DOI: 10.1111/pin.12125

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Immunohistochemical staining patterns of p53 predict the mutational status of TP53 in oral epithelial dysplasia.

Authors:  Keisuke Sawada; Shuji Momose; Ryutaro Kawano; Masakazu Kohda; Tarou Irié; Kenji Mishima; Takahiro Kaneko; Norio Horie; Yasushi Okazaki; Morihiro Higashi; Jun-Ichi Tamaru
Journal:  Mod Pathol       Date:  2021-08-17       Impact factor: 7.842

2.  Primary peri-implant oral intra-epithelial neoplasia/carcinoma in situ: a case report considering risk factors for carcinogenesis.

Authors:  Makoto Noguchi; Hiroaki Tsuno; Risa Ishizaka; Kumiko Fujiwara; Shuichi Imaue; Kei Tomihara; Takashi Minamisaka
Journal:  Int J Implant Dent       Date:  2017-11-16

3.  Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium.

Authors:  Hisashi Hasegawa; Yoshiaki Kusumi; Takeshi Asakawa; Miyoko Maeda; Toshinori Oinuma; Tohru Furusaka; Takeshi Oshima; Mariko Esumi
Journal:  BMC Cancer       Date:  2017-05-26       Impact factor: 4.430

4.  Diagnostic Value of Cytokeratin 17 during Oral Carcinogenesis: An Immunohistochemical Study.

Authors:  Sirima Sanguansin; Theerachai Kosanwat; Rachai Juengsomjit; Sopee Poomsawat
Journal:  Int J Dent       Date:  2021-11-22

5.  Differential immunohistochemical expression of DEC1, CK‑1ε, and CD44 in oral atypical squamous epithelium and carcinoma in situ.

Authors:  Fuyuki Sato; Ujjal K Bhawal; Shoko Osaki; Nao Sugiyama; Kosuke Oikawa; Yasuteru Muragaki
Journal:  Mol Med Rep       Date:  2022-03-10       Impact factor: 2.952

Review 6.  Diagnostic Utility of Cytokeratin 17 Expression in Oral Squamous Cell Carcinoma: A Review.

Authors:  Ankita Gyanchandani; Samarth Shukla; Sunita Vagha; Sourya Acharaya; Ravindra P Kadu
Journal:  Cureus       Date:  2022-07-19

7.  Differentiated vulvar intraepithelial neoplasia (dVIN): the most helpful histological features and the utility of cytokeratins 13 and 17.

Authors:  Shatavisha Dasgupta; Patricia C Ewing-Graham; Folkert J van Kemenade; Helena C van Doorn; Vincent Noordhoek Hegt; Senada Koljenović
Journal:  Virchows Arch       Date:  2018-09-06       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.